Blood Journals Portfolio

New issue of Blood out now featuring A TAG team for achieving deep remissions in BPDCN, MEIS1 guardian USP22 fuels transcription in KMT2Ar leukemia, Securing HMO coverage for HSCT, and more. Explore here:

New issue of Blood out now featuring Epigenetically activating T cells to attack AML, Ex vivo expansion of human long-term HSCs, and more. Explore here:

CMV reactivation is common after CAR T-cell therapy for #LBCL, including in the 2L setting. Corticosteroid exposure is a major risk factor for CMV reactivation. Read in Blood ICT:

RT @ScienceStowers: From the lab to the cover of @BloodPortfolio! 🩸 We're excited to share that research from the Stowers Institute's Li Lab is featured on the cover of the November 5 issue of Blood, a journal of the @ASH_hematology. The study tackles a longstanding challenge in stem cell research: how to expand blood-forming #stem cells in the lab without compromising their ability to rebuild the blood and immune systems. Explore the #research behind the cover:

TAR iPSCs yield fewer MK with precocious maturation and enhanced apoptosis compared to TAR-corrected iPSCs. Gene expression differences involve apoptosis & cell cycle, and splicing differences involve splicing & platelet degranulation. Read in Blood VTH:

Big news for #stemcell and #cordblood research! Read the Blood article here:

NEW research from the Li Lab 🩸 Stowers scientists developed a new system to expand blood-forming stem cells from human cord blood while preserving their long-term function, overcoming a longstanding challenge in stem cell research. Published in @BloodPortfolio. Read more:

Cheers to 10 years of Blood Advances! Founded in December 2016, it's now in the 10 most cited journals in hematology, publishing more peer-reviewed hematology research than any other academic journal worldwide. Learn more and explore testimonials:

In hematopoietic cell transplants, infused donor Tregs prevent #GVHD without impairing #GVL effect, mediated by donor Tcons. Peripheral blood Tregs express CXCR4 at lower intensity than Tcons. Tregs do not home to the BM, leaving Tcons unleashed. #HSCT

New! Drs. Lindsey George of @ChildrensPhila, @MilesHorton9 & @thomaseliotlew of @PeterMacCC & @WEHI_research join to discuss characterization of prothrombotic mechanisms of recombinant FVIII Aurora and using immunosuppressants as tools for in vivo control:

Serum IgG levels declined after CAR-T infusion reaching a nadir at 9 months and remaining suppressed for >2 years after infusion. Older age, low preinfusion IgG levels, and a low CD4/CD8 ratio predisposed patients to post–CAR-T hypogammaglobulinemia.

Ruxolitinib appears to be a tolerable, adjustable, and safe treatment option for second-line treatment of MF. Cytopenias can be managed effectively with close monitoring during ruxolitinib therapy, resulting in low rates of treatment discontinuation.

Syk Y519,520F knockin mice were generated, and they produced homozygous pups that did not follow the Mendelian genetics. Syk Y519,520F mice had intestinal inflammation, which was similar to that observed in phospholipase Cγ2 or SLP76 null mice.

RT @ASH_hematology: 📢 The wait is over: Abstracts for the 68th ASH Annual Meeting and Exposition are live! More than 6,300 abstracts have been accepted for oral and poster presentations at #ASH26. Browse now: #Hematology #HemeOnc

The fetal HSC state is permissive, with mixed in vitro output, whereas adult HSCs exhibit chromatin-level and functional myeloid bias. Fetal lymphoid progenitors exhibit lymphomyeloid chromatin priming with reduced PAX5 motif and enhancer accessibility.

RT @HayderSaeed_MD: Longer PFS, more days of care: the CAR T vs bispecifics trade-off in R/R FL. Retrospective, 228 pts, 17 US centers: median PFS NR vs ~19 mo, OS similar, yr-1 care contact days 58-69 vs 44-49. @majorajay @BloodPortfolio #lymsm #FollicularLymphoma

Experts recommend several NPIs, such as massage and guided imagery, to manage adolescent #SCPC. The BoriZafi framework provides a strong foundation for educational tools that promote effective pain management during pain crises.

"Real-world thrombotic and survival outcomes with ESAs in cancer-related anemia" read the systematic review in Blood VTH:

ELTS score stratified FFS in #CML across treatments, with superior discrimination over Sokal score in the 2G-TKI setting. Read the full article in Blood Advances:

PACSIN2 facilitates clathrin-mediated transferrin receptor (CD71) internalization during terminal erythroid maturation. PACSIN2 deficiency results in mild hypochromic microcytic anemia, altered EBI macrophages, and splenic iron accumulation.

Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis #AML #bloodadvances

Peritransplant 2′-FL is safe and tolerable in pediatric HSCT recipients. 2′-FL reduces intestinal dysbiosis after #HSCT. Read the full article in Blood:

RT @lane_andy: Very happy to have participated in this podcast with @BloodPortfolio about our new paper on the phase 2 trial of TAG-AZA-VEN for #BPDCN

Pain-specific PROs are worse in young adulthood than the preadolescent period in individuals with SCD. Pain duration & frequency are worse in the preadolescent period highlighting the need for longitudinal studies and early intervention. Read in Blood RCI:

Recognizing the importance of PRO data, 85% of Blood and Marrow Transplant Clinical Trials Network trials have included PROs since 2013. Read the full article in Blood Advances:

RT @andiroy: Pleased to see this out @BloodPortfolio

Endothelial IDO1 drives venous thromboembolism via the Trp-Kyn axis in cancer-bearing mice. Read the full study in Blood VTH:

The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities #bloodadvances

TAG-AZA-VEN is a new therapeutic option for patients with BPDCN and may improve on outcomes observed with single-agent TAG. It's effective in both 1L and relapsed BPDCN, with a manageable safety profile, including in an elderly patient population.

New episode of the Blood Podcast out now discussing new drug combinations for #BPDCN and reduced intestinal dysbiosis after #HSCT. Dr. Laurie Sehn interviews Drs. Andrew Lane of @DanaFarber and Pooja Khandelwal of @CincyChildrens on their latest research:

Subcutaneous denecimig administered Q2W was well tolerated, with no safety concerns in HA with/without inhibitors. Most patients with HA experienced zero treated bleeds during denecimig prophylaxis, indicating protection from bleeding. Read here: